Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey. more
Time Frame | KRMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.5% | 0.31% | -1.26% |
1-Month Return | -3.1% | 0.6% | -4.16% |
3-Month Return | 49.08% | -9.44% | -0.46% |
6-Month Return | 62.8% | -5.15% | 3.58% |
1-Year Return | 91.98% | 0.33% | 22.47% |
3-Year Return | 19.35% | 4.53% | 25.13% |
5-Year Return | -25.59% | 35.98% | 77.7% |
10-Year Return | 804.44% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 23.16M | 24.18M | 23.49M | 27.90M | 28.52M | [{"date":"2019-12-31","value":81.22,"profit":true},{"date":"2020-12-31","value":84.78,"profit":true},{"date":"2021-12-31","value":82.37,"profit":true},{"date":"2022-12-31","value":97.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 8.31M | 9.24M | 9.72M | 12.53M | 11.81M | [{"date":"2019-12-31","value":66.33,"profit":true},{"date":"2020-12-31","value":73.76,"profit":true},{"date":"2021-12-31","value":77.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.27,"profit":true}] |
Gross Profit | 14.85M | 14.94M | 13.77M | 15.37M | 16.71M | [{"date":"2019-12-31","value":88.9,"profit":true},{"date":"2020-12-31","value":89.39,"profit":true},{"date":"2021-12-31","value":82.41,"profit":true},{"date":"2022-12-31","value":91.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 64.13% | 61.78% | 58.62% | 55.09% | 58.59% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":96.34,"profit":true},{"date":"2021-12-31","value":91.41,"profit":true},{"date":"2022-12-31","value":85.91,"profit":true},{"date":"2023-12-31","value":91.36,"profit":true}] |
Operating Expenses | 10.85M | 13.74M | 20.80M | 26.15M | 26.98M | [{"date":"2019-12-31","value":40.23,"profit":true},{"date":"2020-12-31","value":50.94,"profit":true},{"date":"2021-12-31","value":77.1,"profit":true},{"date":"2022-12-31","value":96.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 585.68K | (1.25M) | (7.03M) | (10.78M) | (10.27M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-214.24,"profit":false},{"date":"2021-12-31","value":-1200.24,"profit":false},{"date":"2022-12-31","value":-1840.75,"profit":false},{"date":"2023-12-31","value":-1753.52,"profit":false}] |
Total Non-Operating Income/Expense | (3.30M) | 102.92K | 678.18K | 251.30K | 1.06M | [{"date":"2019-12-31","value":-312.46,"profit":false},{"date":"2020-12-31","value":9.73,"profit":true},{"date":"2021-12-31","value":64.12,"profit":true},{"date":"2022-12-31","value":23.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 696.42K | (1.19M) | (6.36M) | (10.68M) | (9.77M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-171.49,"profit":false},{"date":"2021-12-31","value":-913.88,"profit":false},{"date":"2022-12-31","value":-1532.87,"profit":false},{"date":"2023-12-31","value":-1403.41,"profit":false}] |
Income Taxes | 132.07K | 17.80K | (1.80M) | (2.01M) | 3.97M | [{"date":"2019-12-31","value":3.33,"profit":true},{"date":"2020-12-31","value":0.45,"profit":true},{"date":"2021-12-31","value":-45.41,"profit":false},{"date":"2022-12-31","value":-50.76,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 564.35K | (1.21M) | (4.56M) | (8.66M) | (13.74M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-214.77,"profit":false},{"date":"2021-12-31","value":-808.51,"profit":false},{"date":"2022-12-31","value":-1534.71,"profit":false},{"date":"2023-12-31","value":-2434.85,"profit":false}] |
Income From Continuous Operations | 564.35K | (1.21M) | 4.56M | (8.66M) | (13.74M) | [{"date":"2019-12-31","value":12.37,"profit":true},{"date":"2020-12-31","value":-26.56,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-189.82,"profit":false},{"date":"2023-12-31","value":-301.15,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 564.35K | (1.21M) | (4.56M) | (8.66M) | (13.74M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-214.77,"profit":false},{"date":"2021-12-31","value":-808.51,"profit":false},{"date":"2022-12-31","value":-1534.71,"profit":false},{"date":"2023-12-31","value":-2434.85,"profit":false}] |
EPS (Diluted) | 0.10 | (0.03) | (0.10) | (0.20) | (0.16) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-29.13,"profit":false},{"date":"2021-12-31","value":-97.09,"profit":false},{"date":"2022-12-31","value":-194.17,"profit":false},{"date":"2023-12-31","value":-155.34,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KRMD | |
---|---|
Cash Ratio | 1.39 |
Current Ratio | 2.99 |
Quick Ratio | 2.37 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KRMD | |
---|---|
ROA (LTM) | -14.10% |
ROE (LTM) | -50.25% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KRMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.35 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.65 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KRMD | |
---|---|
Trailing PE | NM |
Forward PE | 188.68 |
P/S (TTM) | 5.89 |
P/B | 10.21 |
Price/FCF | NM |
EV/R | 5.52 |
EV/Ebitda | NM |
Repro Med Systems Inc (KRMD) share price today is $4.07
Yes, Indians can buy shares of Repro Med Systems Inc (KRMD) on Vested. To buy Repro Med Systems Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KRMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Repro Med Systems Inc (KRMD) via the Vested app. You can start investing in Repro Med Systems Inc (KRMD) with a minimum investment of $1.
You can invest in shares of Repro Med Systems Inc (KRMD) via Vested in three simple steps:
The 52-week high price of Repro Med Systems Inc (KRMD) is $4.6. The 52-week low price of Repro Med Systems Inc (KRMD) is $1.98.
The price-to-earnings (P/E) ratio of Repro Med Systems Inc (KRMD) is
The price-to-book (P/B) ratio of Repro Med Systems Inc (KRMD) is 10.21
The dividend yield of Repro Med Systems Inc (KRMD) is 0.00%
The market capitalization of Repro Med Systems Inc (KRMD) is $186.56M
The stock symbol (or ticker) of Repro Med Systems Inc is KRMD